Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis

Gerard Socié, Dietger Niederwieser, Nikolas von Bubnoff, Mohamad Mohty, Jeff Szer, Reuven Or, James Garrett, Anirudh Prahallad, Celine Wilke, Robert Zeiser

Blood (2023) 141 (22): 2771–2779.

https://doi.org/10.1182/blood.2022018579

Published: 2023

Includes: Supplemental data

Journal Articles

Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-140403

Published: 2020

Journal Articles

A New Cellular Immunotherapy for the Treatment of Multiple Myeloma without Development of Graft-Versus-Host Disease

Michael A Firer, PhD, Sofi Yado, BSc, MSc, Luboshits Galia, PhD, Reuven Or, MD

Blood (2018) 132 (Supplement 1): 3339.

https://doi.org/10.1182/blood-2018-99-110292

Published: 2018

Journal Articles

G-CSF Vs Haematopoietic Stem Cell Transplantation in Severe Congenital Neutropenia with ELANE Mutation: Role of G-CSF Dose. a Retrospective Controlled Study on Behalf of Saawp (Severe Aplastic Anemia Working Party) of the EBMT, of the Stem Cell Transplant for Immunodeficiency Group in Europe (SCETIDE), of the Severe Chronic Neutropenia French Registry (SCNFR) and Italian Neutropenia Registry (INR)

Blood (2017) 130 (Supplement 1): 2267.

https://doi.org/10.1182/blood.V130.Suppl_1.2267.2267

Published: 2017

Journal Articles

The CXCR4 Antagonist BL-8040 Induces a Robust Mobilization of CD34+CD38−CD45RA−CD90+ CD49f+ HSCs with Long-Term and Secondary Myeloid and Lymphoid Repopulating Activity

Michal Abraham, PhD, Galia Oberkovitz, PhD, Baruch Bulvik, Klein Shiri, Hanna Wald, Orly Eizenberg, Katia Beider, Arnon Nagler, MD, Abi Vainstein, MD, Eyal Benami, Rotem Golan, Eithan Galun, Yoseph Caraco, Reuven Or, MD, Amnon Peled

Blood (2017) 130 (Supplement 1): 660.

https://doi.org/10.1182/blood.V130.Suppl_1.660.660

Published: 2017

Journal Articles

Myeloablative Conditioning for First Allogeneic Hematopoietic Stem Cell Transplantation in Children with ALL: Total Body Irradiation or Chemotherapy? - a Multicenter EBMT-PDWP Study

Andre Manfred Willasch, MD, Christina Peters, MD, Petr Sedlacek, MD, Jean-Hugues Dalle, MD, Stelios Graphakos, MD, Akif Yesilipek, MD, Jacek Wachowiak, Prof MDPhD, Arjan Lankester, MD PhD, Arcangelo Prete, MD, Amir Ali Hamidieh, MD, Marianne Ifversen, Jochen Büchner, MDPhD, Gergely Krivan, MD, Rose-Marie Hamladji, MD, Cristina Diaz de Heredia, MD, Elena Skorobogatova, MD PhD, Gerard Michel, MD, Franco Locatelli, MD PhD, Alice Bertaina, MD PhD, Paul Veys, MD, Sophie Dupont, MD, Reuven Or, MD, Tayfun Guengoer, Olga Aleinikova, MD PhD, Sabina Sufliarska, MD, Mikael Sundin, MD PhD, Jelena Rascon, MD, Ain Kaare, MD, Damir Nemet, MD PhD, Franca Fagioli, MD, Thomas Klingebiel, MD, Jan Styczynski, PhD, Marc B Bierings, MDPhD, Kalman Nagy, MD, Manuel Abecasis, MD, Boris V Afanasyev, MD PhD Professor, Marc Ansari, MD, Arnaud Dalissier, Myriam Labopin, MD, Eric Beohou, Peter Bader, MD PhD

Blood (2017) 130 (Supplement 1): 911.

https://doi.org/10.1182/blood.V130.Suppl_1.911.911

Published: 2017

Journal Articles

Regional Intra-Arterial Steroid Treatment in 113 Patients with Steroid Resistant or Dependent Graft-Versus-Host Disease

Michael Y Shapira, MD, Sheth Vipul, MD, Alexander Klimov, Sigal Griesaro, MD, Panagiotis Tsirigotis, MD PhD, Batia Ronit Avni, MD, Reuven Or, Allan Bloom, MD

Blood (2016) 128 (22): 62.

https://doi.org/10.1182/blood.V128.22.62.62

Published: 2016

Journal Articles

Outcome of BONE Marrow Transplantation in Congenital Diskeratosis: Preliminary DATA from the European Group for BONE Marrow Transplantation (EBMT)

Francesca Fioredda, Elisabeth T Korthof, Simona Iacobelli, Cora Knol, Joan H Veelken, Paul Veys, Ayami Yoshimi, MD, Karin Mellegren, Franca Fagioli, MD, Marco Zecca, MD, Alexey Maschan, Prof, Tracey O'Brien, Miguel Angel Diaz, Owen Smith, Gerard Socie, de la Fuente Josue, Reuven Or, Carlo Dufour, MD

Blood (2015) 126 (23): 3623.

https://doi.org/10.1182/blood.V126.23.3623.3623

Published: 2015

Journal Articles

Thiotepa-Based Conditioning for Allogeneic Stem Cell Transplantation (allo-HSCT) in Acute Lymphoblastic Leukaemia (ALL) - a Survey from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Sandra Eder, MD, Eric Beohou, Myriam Labopin, MD, Jaime Sanz, MD, Jürgen Finke, MD, William Arcese, MD, Reuven Or, Francesca Bonifazi, Agostino Cortelezzi, MD, Ignazio Majolino, MD, Andrea Bacigalupo, MD, Alexandros Spyridonidis, Emilio Paolo Alessandrino, MD, Sebastian Giebel, MD PhD, Mohamad Mohty, MD PhD, Arnon Nagler, MD MSc

Blood (2015) 126 (23): 4316.

https://doi.org/10.1182/blood.V126.23.4316.4316

Published: 2015

Journal Articles

Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation

Blood (2015) 126 (16): 1885–1892.

https://doi.org/10.1182/blood-2015-02-628859

Published: 2015

Journal Articles

Early Apoptotic Cells (ApoCell) As Prophylaxis of Graft-Versus-Host Disease in Myeloablative HLA-Matched Allogeneic Bone Marrow Transplantation Is Safe and Effective: 1 Year Follow-up

Dror Mevorach, Zuckerman Tzila, Arnon Nagler, MD, Jacob M. Rowe, MD, Reuven Or

Blood (2014) 124 (21): 5866.

https://doi.org/10.1182/blood.V124.21.5866.5866

Published: 2014

Journal Articles

Incidence and Risk Factors For Veno-Occlusive Disease Of The Liver After Allogeneic Stem Cell Transplantation Using a Reduced Intensity Regimen

Panagiotis Tsirigotis, Igor B Resnick, Batia Ronit Avni, M.D., Sigal Grisariu, MD, Polina Stepensky, Reuven Or, MD, Michael Y Shapira, MD

Blood (2013) 122 (21): 4562.

https://doi.org/10.1182/blood.V122.21.4562.4562

Published: 2013

Journal Articles

Outcomes Of Allogeneic Cord Blood Transplantation For Leukodystrophies; A Joint Study of Eurocord and “Inborn Errors WP-EBMT”

Blood (2013) 122 (21): 2101.

https://doi.org/10.1182/blood.V122.21.2101.2101

Published: 2013

Journal Articles

Thiotepa-Based Vs TBI-Based Myeloablative Conditioning Prior To Allogeneic Stem Cell Transplantation (HSCT) For Acute Myeloid Leukemia (AML) In First Complete Remission (CR1): A Retrospective Analysis From The ALWP Of The EBMT

Sandra Eder, MD, Myriam Labopin, MD, William Arcese, MD, Reuven Or, MD, Ignazio Majolino, Andrea Bacigalupo, MD, Gennaro de Rosa, Liisa Volin, Dietrich Beelen, MD, Hendrik Veelken, MD PhD, Nicolaas PM Schaap, MD, PhD, Jurgen H Kuball, MD, PhD, Jan Cornelissen, MD, PhD, Arnon Nagler, MD, MSc, Mohamad Mohty, MD, PhD

Blood (2013) 122 (21): 2123.

https://doi.org/10.1182/blood.V122.21.2123.2123

Published: 2013

Journal Articles

Second Allogeneic Stem Cell Transplantation (AlloSCT) In Patients With Relapsed Lymphoma After First Allosct. A Retrospective Study Of The EBMT Lymphoma Working Party

Kristin Horstmann, Ariane Boumendil, PhD, Herve Finel, Jane F. Apperley, MBChB, FRCP, FRCPath, Fabio Ciceri, MD, Juergen Finke, MD, Achiel Van Hoof, Norbert Ifrah, MD, Slawomira Kyrcz-Krzemien, MD, Gustavo Milone, Ghulam J Mufti, FRCP, FRCPath, Elizabeth Naparstek, MD, Reuven Or, MD, Nigel H Russell, MD, Peter Dreger, MD

Blood (2013) 122 (21): 4632.

https://doi.org/10.1182/blood.V122.21.4632.4632

Published: 2013

Journal Articles

Significance of Busulfan Dose Intensity On Outcomes of Hematopoietic Cell Allografting for AML in Second Complete Remission or Beyond: A Report From the EBMT Acute Leukemia Working Party

Ali Bazarbachi, MD, PhD, Myriam Labopin, Mohamed A. Kharfan-Dabaja, MD, Gérard Socié, MD PhD, Nicolaus Kröger, Didier Blaise, MD, Hendrik Veelken, MD PhD, Arancha Bermudez, Reuven Or, MD, Bruno Lioure, MD, Dietrich Beelen, Nathalie Fegueux, MD, Rose-Marie Hamljadi, Arnon Nagler, Mohamad Mohty, MD, PhD

Blood (2012) 120 (21): 1929.

https://doi.org/10.1182/blood.V120.21.1929.1929

Published: 2012

Journal Articles

Single-Infusion of Donor Early Apoptotic Cells (ApoCell) As Prophylaxis of Graft-Versus-Host Disease in Myeloablative HLA-Matched Allogeneic Bone Marrow Transplantati

Dror Mevorach, Inna Reiner, Reuven Or, MD

Blood (2012) 120 (21): 4176.

https://doi.org/10.1182/blood.V120.21.4176.4176

Published: 2012

Journal Articles

Correction of Post-Transplant Hematopoiesis by Novel Use of Mesenchymal-Like Placental Expanded Cells (PLX) Administered Intra-Muscular

Reuven Or, MD, Sigal Grisaro, M.D., Batia Ronit Avni, M.D., Igor Resnick, M.D. PhD, Lilyan Dari, David Shoshani, M.D., Dalia Bracha, RN, MPA, Nurit Beilin, DVM, Limor Lior, MSc, Michael Y. Shapira, MD

Blood (2012) 120 (21): 4133.

https://doi.org/10.1182/blood.V120.21.4133.4133

Published: 2012

Journal Articles

Comparative Efficacy Analysis of Busulfan Dose Intensity Between Two Reduced Intensity Conditioning Regimens (FB2 vs. FB4) for Allogeneic HCT for AML in First Complete Remission: A Report From the EBMT Acute Leukemia Working Party

Mohamed A Kharfan-Dabaja, MD, Myriam Labopin, Ali Bazarbachi, MD, PhD, Rose-Marie Hamljadi, Didier Blaise, MD, Gérard Socié, MD PhD, Bruno Lioure, MD, Arancha Bermudez, MD, Dolores Caballero, MD, Reuven Or, MD, William Arcese, MD, Nathalie Fegueux, MD, Arnon Nagler, Mohamad Mohty, MD, PhD

Blood (2012) 120 (21): 4153.

https://doi.org/10.1182/blood.V120.21.4153.4153

Published: 2012

Journal Articles

A Multi-Center Prospective Randomized Study Comparing Ibritumomab Tiuxetan (Zevalin) and High-Dose BEAM Chemotherapy (Z-BEAM) Vs. BEAM Alone as the Conditioning Regimen Prior to Autologous Stem-Cell Transplantation In Patients with Aggressive Lymphoma; Possible Advantage for Z-BEAM In Low-Risk Patients

Avichai Shimoni, MD, Irit Avivi, MD, Jacob M. Rowe, Moshe Yeshurun, MD, Itai Levi, MD, Reuven Or, MD, Paulina Patachenko, MD, Abraham Avigdor, MD, Tzila Zwas, MD, Arnon Nagler, M.D.

Blood (2010) 116 (21): 686.

https://doi.org/10.1182/blood.V116.21.686.686

Published: 2010

NARROW

Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis

Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study

A New Cellular Immunotherapy for the Treatment of Multiple Myeloma without Development of Graft-Versus-Host Disease

The CXCR4 Antagonist BL-8040 Induces a Robust Mobilization of CD34+CD38−CD45RA−CD90+ CD49f+ HSCs with Long-Term and Secondary Myeloid and Lymphoid Repopulating Activity

Myeloablative Conditioning for First Allogeneic Hematopoietic Stem Cell Transplantation in Children with ALL: Total Body Irradiation or Chemotherapy? - a Multicenter EBMT-PDWP Study

Regional Intra-Arterial Steroid Treatment in 113 Patients with Steroid Resistant or Dependent Graft-Versus-Host Disease

Outcome of BONE Marrow Transplantation in Congenital Diskeratosis: Preliminary DATA from the European Group for BONE Marrow Transplantation (EBMT)

Thiotepa-Based Conditioning for Allogeneic Stem Cell Transplantation (allo-HSCT) in Acute Lymphoblastic Leukaemia (ALL) - a Survey from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation

Early Apoptotic Cells (ApoCell) As Prophylaxis of Graft-Versus-Host Disease in Myeloablative HLA-Matched Allogeneic Bone Marrow Transplantation Is Safe and Effective: 1 Year Follow-up

Incidence and Risk Factors For Veno-Occlusive Disease Of The Liver After Allogeneic Stem Cell Transplantation Using a Reduced Intensity Regimen

Outcomes Of Allogeneic Cord Blood Transplantation For Leukodystrophies; A Joint Study of Eurocord and “Inborn Errors WP-EBMT”

Thiotepa-Based Vs TBI-Based Myeloablative Conditioning Prior To Allogeneic Stem Cell Transplantation (HSCT) For Acute Myeloid Leukemia (AML) In First Complete Remission (CR1): A Retrospective Analysis From The ALWP Of The EBMT

Second Allogeneic Stem Cell Transplantation (AlloSCT) In Patients With Relapsed Lymphoma After First Allosct. A Retrospective Study Of The EBMT Lymphoma Working Party

Significance of Busulfan Dose Intensity On Outcomes of Hematopoietic Cell Allografting for AML in Second Complete Remission or Beyond: A Report From the EBMT Acute Leukemia Working Party

Single-Infusion of Donor Early Apoptotic Cells (ApoCell) As Prophylaxis of Graft-Versus-Host Disease in Myeloablative HLA-Matched Allogeneic Bone Marrow Transplantati

Correction of Post-Transplant Hematopoiesis by Novel Use of Mesenchymal-Like Placental Expanded Cells (PLX) Administered Intra-Muscular

Comparative Efficacy Analysis of Busulfan Dose Intensity Between Two Reduced Intensity Conditioning Regimens (FB2 vs. FB4) for Allogeneic HCT for AML in First Complete Remission: A Report From the EBMT Acute Leukemia Working Party

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only